Literature DB >> 3012081

Is there a common, high-affinity opioid binding site in rat brain?

P A Blurton, A M Broadhurst, M D Wood, M G Wyllie.   

Abstract

At low concentrations, 3H-naloxone apparently bound to two sites, of high (KD 0.50 nM) and low (KD 2.0 nM) affinity. Binding to the high affinity site was preferentially blocked by naloxonazine. This is consistent with the high and low affinity sites representing the mu 1 and mu 2 sites respectively. Binding of 3H-naloxone to the mu 1 and mu 2 sites was differentially inhibited by opioids. Compared to mu 2 binding, DADLE and DAGO preferentially inhibited mu 1 binding. DADLE inhibited the binding of 3H-DAGO potently and in a competitive manner. DAGO inhibited the binding of 3H-DADLE from two sites for which DAGO had high and low affinities. Scatchard analysis indicated that both 3H-DAGO and 3H-DADLE bound to one class of sites, with 3H-DADLE having a 2-3 fold greater Bmax. It is concluded that 3H-opioids bind to at least three sites--mu 1, mu 2 and delta. The mu 1 site represents a high affinity binding site for both opioid peptides and opioid alkaloids. DAGO is a selective ligand for the mu 1 site, whilst DADLE interacts with mu 1 and delta sites with similar affinities.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3012081     DOI: 10.3109/10799898609073926

Source DB:  PubMed          Journal:  J Recept Res        ISSN: 0197-5110


  3 in total

1.  Selective opioid agonist and antagonist competition for [3H]-naloxone binding in amphibian spinal cord.

Authors:  L C Newman; D R Wallace; C W Stevens
Journal:  Brain Res       Date:  2000-11-24       Impact factor: 3.252

2.  Quantitative autoradiographic distribution of meptazinol-sensitive binding sites in rat brain.

Authors:  B A Adler; R R Goodman; G W Pasternak
Journal:  Cell Mol Neurobiol       Date:  1988-12       Impact factor: 5.046

3.  Opposite Roles of δ- and μ-Opioid Receptors in BACE1 Regulation and Alzheimer's Injury.

Authors:  Yuan Xu; Feng Zhi; Gianfranco Balboni; Yilin Yang; Ying Xia
Journal:  Front Cell Neurosci       Date:  2020-04-30       Impact factor: 5.505

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.